PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Bibliographic record
Abstract
Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: Paroxysmal nocturnal hemoglobinuria (PNH) is caused by complement-mediated hemolysis with resultant thrombosis risk and a substantial patient symptom burden. Complement C5 inhibitors (C5i) have improved outcomes by reducing intravascular hemolysis (IVH). Extravascular hemolysis (EVH) continues or becomes evident under C5i treatment, with anemia persisting or recurring in >80% of patients, which may lead to transfusion dependence, fatigue, and impaired quality of life (QoL) (Risitano et al. Blood 2009; Panse et al. Eur J Haematol 2022). Pegcetacoplan is a novel complement C3 inhibitor (C3i) that controls EVH and IVH. In the phase 3 PEGASUS (NCT03500549) trial of patients with persistent anemia despite eculizumab therapy, pegcetacoplan showed head-to-head superiority in mean hemoglobin (Hb) change vs. eculizumab. Pegcetacoplan also demonstrated rapid and sustained Hb stabilization in complement inhibitor-naïve patients in the phase 3 PRINCE (NCT04085601) trial. Pegcetacoplan was approved by the EMA in 2021 for adult PNH patients who are anemic after C5i treatment for ≥3 months. There is currently a need for real-world data on pegcetacoplan usage and effectiveness in the PNH community. Aims: To describe real-world effectiveness of pegcetacoplan in the treatment of adult patients with PNH (Figure 1). QoL and health care resource use, physician and patient satisfaction with the treatment will also be assessed. Methods: COMPLETE is a Phase 4, multicenter, observational study aiming for 200 patients across 70 sites in Europe, the Middle East, Canada, and Australia. The study will include patients (≥18 years) with documented PNH diagnosis who started pegcetacoplan ≤12 months prior enrollment or are prescribed pegcetacoplan at enrollment. The decision to start treatment will be made by the treating physician and independent from the decision to include the patient in the study. Patients who initiated current pegcetacoplan treatment in an interventional trial, those enrolled in a concurrent interventional study or receiving an investigational product ≤3 months prior to start of current pegcetacoplan treatment, will be excluded. The primary endpoint is change in observed Hb level from initiation of pegcetacoplan treatment to 6 months. Changes in lactate dehydrogenase, absolute reticulocyte count, bilirubin, haptoglobin, and ferritin levels will also be assessed from treatment initiation to 6 months. These parameters will be determined at 6-month intervals until the end of study. The alleviation of ongoing anemia will be evaluated by assessing the achievement of Hb ≥12 g/dL and increase in Hb of ≥2 g/dL, likewise at 6-month intervals. Lastly, endpoints reflective of acute events will be examined, including annualized number and units of red blood cell transfusions and acute hemolytic events requiring additional intervention. Adverse events will be collected throughout the study. QoL will be evaluated via patient reported outcome scores. Healthcare resource use will be assessed by number of hospitalizations and emergency room visits. Physician and patient satisfaction with the treatment will also be determined. The total planned study duration is 48 months, with the main part being prospective, and retrospective data being collected for ≤12 months prior to start of pegcetacoplan. Results: Enrollment is expected to begin in Q3 2023 with the final report anticipated in Q1 2028. Summary/Conclusion: Pegcetacoplan is a newly approved, novel PNH therapy. This study aims to describe real-world usage and effectiveness of pegcetacoplan in PNH patients.Keywords: Paroxysmal nocturnal hemoglobinuria (PNH), Quality of life, Complement, Real world data
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.003 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.003 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".